Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Income from Continuing Operations: 2016-2025

Historic Income from Continuing Operations for Assembly Biosciences (ASMB) over the last 9 years, with Sep 2025 value amounting to -$9.2 million.

  • Assembly Biosciences' Income from Continuing Operations rose 4.34% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.2 million, marking a year-over-year increase of 4.03%. This contributed to the annual value of -$40.2 million for FY2024, which is 34.38% up from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Income from Continuing Operations is -$9.2 million, which was down 4.29% from -$8.8 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Income from Continuing Operations peaked at -$8.8 million during Q1 2025, and registered a low of -$62.8 million during Q4 2021.
  • For the 3-year period, Assembly Biosciences' Income from Continuing Operations averaged around -$11.7 million, with its median value being -$9.6 million (2024).
  • In the last 5 years, Assembly Biosciences' Income from Continuing Operations slumped by 461.45% in 2021 and then surged by 52.10% in 2024.
  • Quarterly analysis of 4 years shows Assembly Biosciences' Income from Continuing Operations stood at -$62.8 million in 2021, then reached -$11.0 million in 2023, then increased by 5.72% to -$10.3 million in 2024, then increased by 4.34% to -$9.2 million in 2025.
  • Its Income from Continuing Operations stands at -$9.2 million for Q3 2025, versus -$8.8 million for Q2 2025 and -$8.8 million for Q1 2025.